Pharmaceutical

Cardurion closes $260m in Series B to develop cardiovascular pipeline

The funds will finance late-stage trials of CRD-750, a PDE9 inhibitor for heart failure, and CRD-4730, a CaMKII inhibitor.

Jul 18, 2024 - 04:00
Cardurion closes $260m in Series B to develop cardiovascular pipeline
The funds will finance late-stage trials of CRD-750, a PDE9 inhibitor for heart failure, and CRD-4730, a CaMKII inhibitor.
Read the original article

Tags:

Previous Article

CatalYm secures $150m to advance GDF-15-targeting immune modulator   

Next Article

The US Biosecure Act threatens to destabilise the pharmaceutical industry 

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: ImmunoGen drug prolongs survival of women with advanced ovarian cancer

STAT+: ImmunoGen drug prolongs survival of women with a...

Jun 4, 2023

Former surgeon general Jerome Adams tries to outrun the shadow of the president he served

Former surgeon general Jerome Adams tries to outrun the...

Mar 24, 2023

Santen, Arctic Vision sign deal for ARVN001 to treat UME

Santen, Arctic Vision sign deal for ARVN001 to treat UME

Nov 9, 2024